These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 11053058

  • 1. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
    Breedveld FC, Dayer JM.
    Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
    [Abstract] [Full Text] [Related]

  • 2. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
    Herrmann ML, Schleyerbach R, Kirschbaum BJ.
    Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action of leflunomide in rheumatoid arthritis.
    Fox RI.
    J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of action for leflunomide in rheumatoid arthritis.
    Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ.
    Clin Immunol; 1999 Dec; 93(3):198-208. PubMed ID: 10600330
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
    Cao WW, Kao PN, Chao AC, Gardner P, Ng J, Morris RE.
    J Heart Lung Transplant; 1995 Dec; 14(6 Pt 1):1016-30. PubMed ID: 8719445
    [Abstract] [Full Text] [Related]

  • 6. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
    Moon SJ, Kim EK, Jhun JY, Lee HJ, Lee WS, Park SH, Cho ML, Min JK.
    J Transl Med; 2017 Feb 13; 15(1):31. PubMed ID: 28193225
    [Abstract] [Full Text] [Related]

  • 7. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
    Rückemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, Simmonds HA.
    J Biol Chem; 1998 Aug 21; 273(34):21682-91. PubMed ID: 9705303
    [Abstract] [Full Text] [Related]

  • 8. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.
    Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B.
    Ann Rheum Dis; 2003 Apr 21; 62(4):297-302. PubMed ID: 12634225
    [Abstract] [Full Text] [Related]

  • 9. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
    Xu X, Williams JW, Gong H, Finnegan A, Chong AS.
    Biochem Pharmacol; 1996 Aug 23; 52(4):527-34. PubMed ID: 8759024
    [Abstract] [Full Text] [Related]

  • 10. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
    Magne D, Mézin F, Palmer G, Guerne PA.
    Inflamm Res; 2006 Nov 23; 55(11):469-75. PubMed ID: 17122964
    [Abstract] [Full Text] [Related]

  • 11. Leflunomide and malononitrilamides.
    Silva Júnior HT, Morris RE.
    Am J Med Sci; 1997 May 23; 313(5):289-301. PubMed ID: 9145039
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
    Greene S, Watanabe K, Braatz-Trulson J, Lou L.
    Biochem Pharmacol; 1995 Sep 07; 50(6):861-7. PubMed ID: 7575649
    [Abstract] [Full Text] [Related]

  • 13. Suppression of experimental autoimmune neuritis by leflunomide.
    Korn T, Toyka K, Hartung HP, Jung S.
    Brain; 2001 Sep 07; 124(Pt 9):1791-802. PubMed ID: 11522581
    [Abstract] [Full Text] [Related]

  • 14. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
    Vergne-Salle P, Léger DY, Bertin P, Trèves R, Beneytout JL, Liagre B.
    Cytokine; 2005 Sep 07; 31(5):335-48. PubMed ID: 16099671
    [Abstract] [Full Text] [Related]

  • 15. Leflunomide: a review of its use in active rheumatoid arthritis.
    Prakash A, Jarvis B.
    Drugs; 1999 Dec 07; 58(6):1137-64. PubMed ID: 10651393
    [Abstract] [Full Text] [Related]

  • 16. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
    Vrenken TE, Buist-Homan M, Kalsbeek AJ, Faber KN, Moshage H.
    J Hepatol; 2008 Nov 07; 49(5):799-809. PubMed ID: 18809221
    [Abstract] [Full Text] [Related]

  • 17. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
    Chong AS, Huang W, Liu W, Luo J, Shen J, Xu W, Ma L, Blinder L, Xiao F, Xu X, Clardy C, Foster P, Williams JA.
    Transplantation; 1999 Jul 15; 68(1):100-9. PubMed ID: 10428276
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
    Doscas ME, Williamson AJ, Usha L, Bogachkov Y, Rao GS, Xiao F, Wang Y, Ruby C, Kaufman H, Zhou J, Williams JW, Li Y, Xu X.
    Neoplasia; 2014 Oct 15; 16(10):824-34. PubMed ID: 25379019
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
    Li Y, Yi L, Cheng S, Wang Y, Wang J, Sun J, Zhang Q, Xu X.
    J Gen Virol; 2021 Mar 15; 102(3):. PubMed ID: 33416466
    [Abstract] [Full Text] [Related]

  • 20. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
    Knecht W, Löffler M.
    Biochem Pharmacol; 1998 Nov 01; 56(9):1259-64. PubMed ID: 9802339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.